



### **Translational Research in Retinoblastoma**

Retinoblastoma from the cell of origin to molecular targets.  
**François Radvanyi.** Institut Curie, Paris, France.

### **How we evaluate children with retinoblastoma in 2016**

Moderator: **Jaume Català.** Hospital Sant Joan de Déu, Barcelona, Spain.

Ophthalmological evaluation, controversies in grouping systems and when to use new technologies.

**Manoj Parulekar.** Birmingham Children's Hospital, Birmingham, UK.

The updated TNM staging system for retinoblastoma.

**Brenda Gallie.** Sick Children's Hospital, Toronto, Canada.

Staging of patients with retinoblastoma: Who needs bone marrow and lumbar puncture for staging?

**Carlos Leal-Leal.** Instituto Nacional de Pediatría, Ciudad de México, México.

Imaging studies in retinoblastoma. Controversies on diagnosis and follow-up. **Pim de Graaf.** VUMC, Amsterdam, Netherlands.

### **Conservative treatment of retinoblastoma in 2016**

Moderator: **Antonino Romanzo.** Ospedale Bambino Gesù, Roma, Italy.

Conservative therapy. Results of Institut Curie. **Laurence Desjardins.** Institut Curie, Paris, France.

Intra-arterial chemotherapy. The first 10 years of experience in New York. **Jasmine Francis.** Memorial Sloan-Kettering Cancer Center, New York, USA.

How we treat relapsed intraocular retinoblastoma? **Francis Munier.** CHUV, Lausanne, Switzerland.

Pharmacokinetics of the different routes for chemotherapy in retinoblastoma. Translation to the clinic.

**Paula Schaiquevich.** Hospital JP Garrahan, Buenos Aires, Argentina

Intra-arterial chemotherapy from eye salvage to first line treatment. Experience in Siena. **Doris Hadjistilianou.** University of Siena, Siena, Italy

### **Estimating the risk of extraocular relapse in retinoblastoma. Views and controversies from major groups**

Moderator: **Nathalia Grigorovski** Instituto Nacional do Cancer, Rio de Janeiro, Brazil

Minimally disseminated disease in retinoblastoma. Is it useful for guiding the rationale for treatment of high risk retinoblastoma? **Guillermo Chantada.** Hospital Sant Joan de Déu, Barcelona, Spain and Hospital JP Garrahan, Buenos Aires, Argentina.

Adjuvant therapy for high risk retinoblastoma. The Institut Curie. Experience. **Isabelle Aerts.** Institut Curie, Paris, France.

Treatment of extraocular retinoblastoma. **Ira Dunkel.** Memorial Sloan-Kettering Cancer Center, New York, USA.

Round table and case discussion: How to improve results in CNS + retinoblastoma. Which patients should receive adjuvant therapy?

### **International Initiatives**

The European retinoblastoma group. EURbG.

**Guillermo Chantada.** Hospital Sant Joan de Déu, Barcelona, Spain and Hospital JP Garrahan, Buenos Aires, Argentina.

**Francis Munier.** CHUV, Lausanne, Switzerland.

Parental support groups perspective.

**Moni and Gregor König.** Kinderaugenkrebsstiftung, Bonn, Germany.

Retinoblastoma in less developed countries global programs for retinoblastoma control **Carlos Rodriguez-Galindo.** St Jude Children's Research Hospital, Memphis, USA.